From the publishers of JADPRO

MPN Resource Center


Pelabresib in combination with ruxolitinib for Janus kinase inhibitor treatment-naive patients with myelofibrosis: Results of the MANIFEST-2 randomized, double-blind, phase 3 study

Last Updated: Monday, January 29, 2024

Results from the MANIFEST-2 phase 3 study of pelabresib plus ruxolitinib vs placebo plus ruxolitinib in patients with treatment-naïve intermediate-1/2 or high-risk myelofibrosis demonstrated efficacy in achieving spleen volume reduction of ≥35% at week 24 in 66% of patients in the pelabresib plus ruxolitinib arm vs 35% in patients on placebo plus ruxolitinib (P<0.0001). Additionally, while not statistically significant, ≥50% reduction in total symptom score at 24 weeks was achieved by 52.3% of the pelabresib plus ruxolitinib arm compared with 46.3% of the placebo plus ruxolitinib arm, and higher hemoglobin levels were experienced by patients treated with pelabresib plus ruxolitinib.  

2023 American Society of Hematology Annual Meeting Abstract
News & Literature Highlights

British Journal of Haematology

‘MPN Genomic Calculator’: real‐life use in a young population with essential thrombocythaemia


Significant association of cutaneous adverse events with hydroxyurea: results from a prospective non-interventional study in BCR-ABL1-negative myeloproliferative neoplasms (MPN) - on behalf of the German Study Group-MPN

Thrombosis Research

Patient outcomes in myeloproliferative neoplasm-related thrombosis: Insights from the National Inpatient Sample

British Journal of Haemtology

Real‐world non‐interventional long‐term post‐authorisation safety study of ruxolitinib in myelofibrosis

Cancer Medicine

Depressive symptoms and myeloproliferative neoplasms: Understanding the confounding factor in a complex condition

Expert Review of Hematology

Developing strategies to reduce the duration of therapy for patients with myeloproliferative neoplasms

European Society for Medical Oncology (ESMO) Congress 2021 Abstract

Final results of a phase II study of tipifarnib in chronic myelomonocytic leukemia (CMML) and other myelodysplastic/myeloproliferative neoplasms (MDS/MPN)

European Society for Medical Oncology (ESMO) Congress 2021 Abstract

Treatment outcomes and antibody immunity to SARS-CoV-2 in patients with hematological malignancies

Annals of Hematology

Evaluation of the need for cytoreduction and its potential carcinogenicity in children and young adults with myeloproliferative neoplasms

Clinical Lymphoma Myeloma and Leukemia

Mortality and causes of death of patients with polycythemia vera: analysis of the REVEAL prospective, observational study